NCT06394622

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors

Name: Clinical Trial NCT06394622
Creator: Fudan University
Keywords: Solid Tumor, Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells, Phase 1, combination product, clinical trial, China

Fudan University·Phase 1·ClinicalTrials.gov·combination productRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Solid Tumor
Drug/Device/Intervention: Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells
Study type: Interventional
Intervention type: combination product

Sponsor & location

Primary sponsor: Fudan University
Location: Shanghai, China

Timeline & enrollment

Phase: Phase 1
Start date: Apr 11, 2024
End date: Jun 28, 2026
Enrollment: 12 participants

Primary outcome

ORR of CD70 CAR-NKT cell dynamics

Summary

This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC729 in the treatment of advanced malignant solid tumors.  Condition or disease:advanced malignant solid tumors. Intervention/treatment:Biological: CD70 CAR-NKT cells. Phase:I

ICD-10 classifications

Malignant neoplasm: Connective and soft tissue, unspecifiedCarcinoma in situ, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissueMalignant neoplasm: Lip, unspecified, inner aspect

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06394622
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06394622 through Pure Global AI's free database. This Phase 1 trial is sponsored by Fudan University and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.